{"id":6431,"date":"2022-08-04T17:33:39","date_gmt":"2022-08-04T09:33:39","guid":{"rendered":"https:\/\/www.excelsiormedical.com.tw\/?p=6431"},"modified":"2023-01-09T16:53:16","modified_gmt":"2023-01-09T08:53:16","slug":"the-board-of-directors-approved-q2-2022-consolidated-financial-statements","status":"publish","type":"post","link":"https:\/\/www.excelsiormedical.com.tw\/en\/investors\/the-board-of-directors-approved-q2-2022-consolidated-financial-statements\/","title":{"rendered":"The Board of Directors approved Q2 2022 consolidated financial statements."},"content":{"rendered":"<p>&nbsp;<\/p>\n<table class=\"hasBorder\">\n<tbody>\n<tr>\n<td class=\"tblHead\">SEQ_NO<\/td>\n<td class=\"odd\">\u00a01<\/td>\n<td class=\"tblHead\">Date of announcement<\/td>\n<td class=\"odd\">\u00a02022\/08\/04<\/td>\n<td class=\"tblHead\">Time of announcement<\/td>\n<td class=\"odd\">17:33:19<\/td>\n<\/tr>\n<tr>\n<td class=\"tblHead\">Subject<\/td>\n<td class=\"odd\" colspan=\"5\">\n<pre>The Board of Directors approved Q2 2022\r\nconsolidated financial statements.<\/pre>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"tblHead\">Date of events<\/td>\n<td class=\"odd\">2022\/08\/04<\/td>\n<td class=\"tblHead\">To which item it meets<\/td>\n<td class=\"odd\" colspan=\"3\">paragraph 31<\/td>\n<\/tr>\n<tr>\n<td class=\"tblHead\">Statement<\/td>\n<td class=\"odd\" colspan=\"5\">\n<pre>1.Date of submission to the board of directors or \r\n  approval by the board of directors:2022\/08\/04\r\n2.Date of approval by the audit committee:2022\/08\/04\r\n3.Start and end dates of financial reports or annual \r\n  self-assessed financial information of the reporting\r\n  period (XXXX\/XX\/XX~XXXX\/XX\/XX): 2022\/01\/01~2022\/06\/30\r\n4.Operating revenue accumulated from 1\/1 to end of the \r\n  period (thousand NTD):3,382,621\r\n5.Gross profit (loss) from operations accumulated from \r\n  1\/1 to end of the period (thousand NTD):740,566\r\n6.Net operating income (loss) accumulated from 1\/1 to \r\n  end of the period (thousand NTD):308,689\r\n7.Profit (loss) before tax accumulated from 1\/1 to end\r\n  of the period (thousand NTD):459,855\r\n8.Profit (loss) accumulated from 1\/1 to end of the period\r\n  (thousand NTD):369,907\r\n9.Profit (loss) during the period attributable to owners \r\n  of parent accumulated from 1\/1 to end of the period\r\n  (thousand NTD):308,122\r\n10.Basic earnings (loss) per share accumulated from 1\/1 \r\n   to end of the period (NTD):2.18\r\n11.Total assets end of the period (thousand NTD):\r\n   16,014,344\r\n12.Total liabilities end of the period (thousand NTD):\r\n   6,199,849\r\n13.Equity attributable to owners of parent end of the \r\n   period (thousand NTD):7,810,783\r\n14.Any other matters that need to be specified:None.<\/pre>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; SEQ_NO \u00a01 Date of announcement \u00a02022\/08\/04 Time of announcement 17:33:19 Subject The Board of Directors approved Q2 2022 consolidated financial statements. Date of events 2022\/08\/04 To which item it meets paragraph 31 Statement 1.Date of submission to the board of directors or approval by the board of directors:2022\/08\/04 2.Date of approval by the audit &hellip;<\/p>\n<p class=\"read-more\"> <a class=\"\" href=\"https:\/\/www.excelsiormedical.com.tw\/en\/investors\/the-board-of-directors-approved-q2-2022-consolidated-financial-statements\/\"> <span class=\"screen-reader-text\">The Board of Directors approved Q2 2022 consolidated financial statements.<\/span> Read More &raquo;<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[72,102],"tags":[],"class_list":["post-6431","post","type-post","status-publish","format-standard","hentry","category-investors","category-material-information"],"_links":{"self":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts\/6431","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/comments?post=6431"}],"version-history":[{"count":4,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts\/6431\/revisions"}],"predecessor-version":[{"id":6438,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts\/6431\/revisions\/6438"}],"wp:attachment":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/media?parent=6431"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/categories?post=6431"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/tags?post=6431"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}